Temperature-controlled logistics company Cryoport, has been selected by allogeneic cell therapy company, Celularity, to utilize its complete range of temperature-controlled solutions.
 
Celularity is a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from human placentas through its proprietary IMPACT platform across immuno-oncology, inflammatory and age-related diseases. The agreement will give Celularity access to Cryoport’s full suite of temperature-controlled logistics solutions, including the Cryoport Express shippers, the Cryoportal Logistics Management Platform, Smartpak II Condition Monitoring System and 24/7/365 logistics support.
 
“We are proud to support Celularity’s clinical programs for the development of transformative allogeneic cell therapies,” said Jerrell Shelton, chief executive officer, Cryoport. “Cryoport’s end-to-end, industry-leading, temperature-controlled logistics solutions protect the biologic commodities that underpin these potentially ground-breaking therapies and play a vital role in their development.”
 
John R. Haines, chief administrative officer, Celularity, said, “Celularity’s IMPACT platform seamlessly integrates biosourcing through advanced cell manufacturing and productization of allogeneic placental-derived cell therapeutics. Industry-leading supply chain management tools are critical to our ability to deliver transformative, on-demand, off-the-shelf therapeutic options to patients in the United States and worldwide. We look forward to partnering with Cryoport for cell therapy product logistics management.”
 
Cryoport supports over 357 clinical trials globally as well as blockbuster FDA-approved CAR-T therapies from Novartis and Gilead.